You are here: Industry Insights > CTLA-4

News List

HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021 prnasia
July 27, 2021
Harbour BioMed announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumors will be presented as an e-poster at the 2021 European Society for ...
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody prnasia
May 12, 2021
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) ...
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors prnasia
September 22, 2020
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human ...
Agenus Commences Trial of Next-Gen CTLA-4 with PD-1 Antibody americanpharmaceuticalreview
December 20, 2019
Agenus announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor.
BioAtla & BeiGene Enter Development Pact contractpharma
April 15, 2019
Agreement also covers the manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).